DBV Technologies

DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy. We are committed to developing safe and effective therapies for food allergic patients, for whom there are no currently approved treatments. DBV is developing epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. Our development program includes peanut and milk allergy, as well as potential applications in the field of food allergies.

Sponsor Category: 
Other Sponsors